FDA Officials Join Big Pharma After Approving $26,500 Taxpayer-Funded Drug
Three senior FDA officials transitioned to pharmaceutical roles shortly after clearing Biogen’s Leqembi for the commercial market. This revolving door coincided with a $3.5 million lobbying blitz that secured taxpayer-funded Medicare coverage for a drug priced well above independent value assessments.
FDA leaders joined the pharmaceutical industry after facilitating a $17 billion taxpayer-funded market for an Alzheimer's drug priced 20% above its clinical value.
Billy Dunn, the former Director of the FDA Office of Neuroscience, resigned his post in February 2023. Within months, he joined the board of Prothena and launched a consultancy serving the biotech sector. His departure came just as the FDA was fast-tracking Leqembi (lecanemab), a monoclonal antibody for Alzheimer’s developed by Biogen and Eisai. Dunn is not an outlier; Eric Bastings, the former Deputy Director of the same office, moved to a senior role at Ionis Pharmaceuticals—a key Biogen partner—while clinical reviewer Chantal Beck transitioned to private sector consulting for monoclonal antibody submissions.
While these officials navigated the revolving door, Biogen and Eisai executed a $3.5 million lobbying campaign specifically targeting Medicare reimbursement policies. The investment focused on the 'Access to Innovative Treatments Act' and pressured the Centers for Medicare & Medicaid Services (CMS) to reverse its 'Coverage with Evidence Development' (CED) restrictions. This regulatory maneuver succeeded: CMS granted broad coverage for Leqembi upon its traditional approval in July 2023, bypassing the rigorous evidence-gathering requirements usually applied to high-cost biologics with safety risks.
The financial stakes are massive. Biogen set Leqembi’s list price at $26,500 per year, despite an independent analysis by the Institute for Clinical and Economic Review (ICER) suggesting a fair value between $8,900 and $21,500. By securing a policy change that opens the drug to 6.7 million Medicare beneficiaries, the manufacturers have tapped into a potential $17.7 billion annual revenue stream. This market penetration is funded almost entirely by U.S. taxpayers through Medicare Part B.
Mainstream reporting has focused on Leqembi as a medical 'breakthrough' for slowing cognitive decline. However, clinical data shows the drug provides a modest 27% slowing of decline—a margin many clinicians argue may not be noticeable to patients—while carrying significant risks of brain swelling and bleeding (ARIA). The FDA granted approval despite these concerns and the procedural shadow of its previous Alzheimer’s drug, Aduhelm, where leadership ignored its own advisory committee’s recommendation to reject the drug.
For the average American senior, this regulatory capture has a direct cost. The massive projected expenditure for Leqembi is a primary driver behind rising Medicare Part B premiums. Even seniors who never receive the drug will see their monthly checks reduced to subsidize a corporate product that was priced by the manufacturer, approved by their future employees, and protected by their lobbyists.
Summary
Three senior FDA officials transitioned to pharmaceutical roles shortly after clearing Biogen’s Leqembi for the commercial market. This revolving door coincided with a $3.5 million lobbying blitz that secured taxpayer-funded Medicare coverage for a drug priced well above independent value assessments.
⚡ Key Facts
- Three senior FDA officials, including Billy Dunn and Eric Bastings, moved to industry-aligned roles within 12 months of Leqembi’s regulatory milestones.
- Biogen and Eisai spent $3.5 million on direct lobbying to influence CMS coverage and ensure Medicare Part B funding.
- The drug's $26,500 list price exceeds independent fair-value assessments by as much as $17,600 per patient.
- CMS bypassed standard 'Coverage with Evidence Development' (CED) protocols to allow broad reimbursement for the drug.
- Projected market penetration of 10% could cost taxpayers $17.7 billion annually, driving up Medicare premiums for all beneficiaries.
Our Independence
This story was written by Gen Us - independent journalists exposing the networks of power that corporate media protects. No hedge fund owns us. No billionaire edits our headlines. We answer only to you, our readers.